New Clinical Trials Open for Sarcomas and Solid Tumors
Two exciting early phase clinical trials are underway at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, that leverage novel classes of drugs and exploit how proteins can be targeted and/or removed to stop uncontrolled cell division that occurs in sarcomas and solid tumors. For BRAF B600 […]
Investigating New Treatment Options – New Clinical Trial: First Personalized Vaccine for Small Cell Lung Cancer
At Siteman Cancer Center, a new clinical trial is underway that will evaluate the benefits of a neoantigen vaccine in combination with chemotherapy and immunotherapy to treat small cell lung cancer (SCLC). The rapidly growing, aggressive cancer represents about 15% of all lung cancers in the U.S. SCLC has low survival rates, with most cases […]
Newly approved drug effective against lung cancer caused by genetic mutation
The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with […]